ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 31

Anti Citrullinated Protein Antibodies From Synovial Fluid of Rheumatoid Arthritis Patients Enhance Osteoclastogenesis

Akilan Krishnamurthy1, Nancy Vivar Pomiano2, Catia Cerqueira3, Elena Ossipova3, Karin Lundberg4, Ulrike Harre5, Vivianne Malmström6, Per Johan Jakobsson7, Lars Klareskog8, Georg Schett9 and Anca Catrina3, 1Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 3Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 4Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 5Institute for Clinical Immunology, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 6Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 7Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 8Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, 9Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, anti-citrullinated protein/peptide antibodies (ACPA), Bone metabolism and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Biology and Pathology of Bone and Joint

Session Type: Abstract Submissions (ACR)

Background/Purpose: Presence of anti CCP2 antibodies identifies a subgroup of RA patients that are more prone to develop bone erosions. We hypothesized that anti CCP2 IgG might have a direct effect on bone, and thus investigated the effect of anti CCP2 IgG isolated from synovial fluid (SF) of RA patients on osteoclastogenesis and bone destruction in an in vitro system.

Methods: SF (n=26) samples were collected from RA patients with anti-CCP2 IgG levels above 300AU/ml. Total IgG was isolated on Protein G columns, before applied to CCP2 affinity columns, kindly donated by EuroDiagnostica. A pool of the purified anti-CCP IgG fractions, as well as a pool of the corresponding column flow through IgG fractions were tested for the ability to influence osteoclastogenesis and bone destruction. CD14 positive cells isolated by positive selection from peripheral blood of healthy individuals were cultured in the presence of GM-CSF and IL-4 to generate immature dendritic cells. After 6 days of culture, cells were incubated in the presence of RANKL and M-CSF, with or without CCP2 IgG or flow through IgG (at a final concentration of 100ng/ml) for an additional 12 days. Osteoclasts formation was evaluated as total number of multinucleated TRAP positive cells. In parallel cultures were grown on osteologic discs and % of resorbed out of total disc areas were evaluated by computer assisted image analyses

Results: The CCP2 IgG pool significantly increased the formation of osteoclasts. In contrast the pool of the flow through IgG did not stimulate RANKL-driven osteoclastogenesis from immature dendritic cells. When assessing bone destruction CCP2 IgG but not flow through IgG was able to increase the percentage of synthetic bone resorption areas.

Conclusion: Here, we demonstrate that ACPA IgG, isolated from synovial fluid of RA patients, have the ability to enhance the RANKL-driven osteocalstogenesis from immature dendritic cells. Our findings suggest that ACPA might have a direct pathogenic effect in RA associated bone destruction.


Disclosure:

A. Krishnamurthy,
None;

N. Vivar Pomiano,
None;

C. Cerqueira,
None;

E. Ossipova,
None;

K. Lundberg,
None;

U. Harre,
None;

V. Malmström,
None;

P. J. Jakobsson,
None;

L. Klareskog,
None;

G. Schett,
None;

A. Catrina,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-citrullinated-protein-antibodies-from-synovial-fluid-of-rheumatoid-arthritis-patients-enhance-osteoclastogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology